CRO spécialisée en drug discovery, services précliniques et cliniques
 

Publications de référence Oncomedics

Publications de Référence Oncomedics

CliniSciences présente une sélection de publications de référence relatives aux technologies et approches développées par OncoMedics, notamment les tests de chimiosensibilité ex vivo, les assays ATP-based, les organoïdes et les modèles prédictifs pour la chimiothérapie individualisée en oncologie, particulièrement dans le cancer colorectal et les métastases péritonéales.

Publications Sélectionnées

The Oncogramme® Predicts the Response of Metastatic Ovarian Cancer to Chemotherapeutic Treatment: Link with Patient Care Pathway through Peritoneal Cancer Index, RECIST Criteria 1.1 and Resective Surgical Operability: A Pilot Study
Stéphanie GIRAUD, Tristan GAUTHIER, Ophélie PASINI-CHABOT, Renaud MARTIN, Véronique FERMEAUX, Sandrine LUCE, Pierre-Marie PREUX, Elise DELUCHE, Nicole TUBIANA-MATHIEU, Laurence VENAT, Anne FLOQUET, Frédéric GUYON, Joëlle MOLLARD, Aurélie PERRAUD et Christophe LAUTRETTE
J Cancer Res Therap Oncol. 2026; vol 14: 102.
Clinical value of an adenosine triphosphate-based chemotherapy response assay in resectable stage III colorectal cancer
Chan Dong Kim, So Hyun Kim, Sang Hoon Jung, Jae Hwang Kim
Ann Surg Treat Res. 2019 Aug;97(2):93-102.
Predictive Value of Ex Vivo Chemosensitivity Assays for Individualized Cancer Chemotherapy: A Meta-Analysis
Kristin Blom, Peter Nygren, Rolf Larsson, Claes R Andersson
SLAS Technol. 2017 Jun;22(3):306-314.
Organoids as preclinical models to improve intraperitoneal chemotherapy effectiveness for colorectal cancer patients with peritoneal metastases: Preclinical models to improve HIPEC
P Roy, C Canet-Jourdan, M Annereau, O Zajac, M Gelli, S Broutin, L Mercier, A Paci, F Lemare, M Ducreux, D Elias, D Malka, V Boige, D Goéré, F Jaulin
Int J Pharm. 2017 Oct 5;531(1):143-152.
Development and Applicability of Integrative Tumor Response Assays for Metastatic Colorectal Cancer
YONG SIK YOON, CHAN WOOK KIM, SEON AE ROH, DONG HYUNG CHO, TAE WON KIM, MOON BO KIM and JIN CHEON KIM
Anticancer Research. 2017 Mar;37(3):1297-1303.
Clinical Significance of 5-Fluorouracil Chemosensitivity Testing in Patients with Colorectal Cancer
Woong Bae Ji, Jun Won Um, Je Seock Ryu, Kwang Dae Hong, Jung Sik Kim, Byung Wook Min, Sung Yeop Joung, Ju Han Lee, Young Sik Kim
Anticancer Res. 2017 May;37(5):2679-2682.
Ex Vivo Assessment of Drug Activity in Patient Tumor Cells as a Basis for Tailored Cancer Therapy
Kristin Blom, Peter Nygren, Jonathan Alvarsson, Rolf Larsson, Claes R Andersson
J Lab Autom. 2016 Feb;21(1):178-87. [PDF]
In Vitro Adenosine Triphosphate-Based Chemotherapy Response Assay as a Predictor of Clinical Response to Fluorouracil-Based Adjuvant Chemotherapy in Stage II Colorectal Cancer
Hye Youn Kwon, Im-Kyung Kim, Jeonghyun Kang, Seung-Kook Sohn, Kang Young Lee
Cancer Res Treat. 2016 Jul;48(3):970-7.
Precision medicine for cancer with next-generation functional diagnostics
Adam A. Friedman, Anthony Letai, David E. Fisher and Keith T. Flaherty
Nat Rev Cancer. 2015 Dec;15(12):747-56. [PDF]
Role of Conventional Chemosensitivity Test and Tissue Biomarker Expression in Predicting Response to Treatment of Peritoneal Carcinomatosis From Colon Cancer
Chiara Arienti, Anna Tesei, Giorgio Maria Verdecchia, Massimo Framarini, Salvatore Virzì, Antonio Grassi, Emanuela Scarpi, Livia Turci, Rosella Silvestrini, Dino Amadori, Wainer Zoli
Clinical Colorectal Cancer. 2013 Jun;12(2):122-127. [PDF]
Clinical potential of the anticancer drug sensitivity test for patients with synchronous stage IV colorectal cancer
Katsushi Takebayashi, Eiji Mekata, Hiromichi Sonoda, Tomoharu Shimizu, Yoshihiro Endo, Tohru Tani
Cancer Chemother Pharmacol. 2013;72:217-222. [PDF]
Applicability of Histoculture Drug Response Assays in Colorectal Cancer Chemotherapy
Yong Sik Yoon, Chan Wook Kim, Seon Ae Roh, Dong Hyung Cho, Gyu Pyo Kim, Yong Sang Hong, Tae Won Kim, Moon Bo Kim, Jin Cheon Kim
Anticancer Res. 2012 Aug;32(8):3581-6. [PDF]

Intéressé(e) par les technologies Oncomedics ?

Contactez-nous pour plus d’informations sur les tests de chimiosensibilité ex vivo, les assays prédictifs ou pour discuter d’applications cliniques et précliniques.

Contactez-nous à l’adresse tech@clinisciences.com

Nous contacter